false000185090600018509062023-08-092023-08-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): August 9, 2023 |
Singular Genomics Systems, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
001-40443 |
81-2948451 |
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
3010 Science Park Road San Diego, California 92121 |
|
(858) 333-7830 (Registrant’s address of principal executive offices and telephone number, including area code) |
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of Each Class
|
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered
|
Common Stock, par value $0.0001 per share |
|
OMIC |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 2.02 Results of Operations and Financial Condition. |
On August 9, 2023, Singular Genomics Systems, Inc. (the “Company”) issued a press release regarding the Company’s financial results for the quarter ended June 30, 2023. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
|
Item 9.01 Financial Statements and Exhibits. |
(d) Exhibits
|
|
|
Exhibit Number |
|
Description |
99.1 |
|
Press Release dated August 9, 2023. |
104 |
|
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Singular Genomics Systems, Inc. |
|
|
|
|
Dated: |
August 9, 2023 |
By: |
/s/ Dalen Meeter |
|
|
|
Dalen Meeter Chief Financial Officer Principal Financial Officer and Principal Accounting Officer |
EX-99.1
Singular Genomics Reports Recent Highlights and Second Quarter 2023 Financial Results
San Diego, CA, August 9, 2023 – Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2023.
“We made significant advancements across our operations, manufacturing and commercial infrastructure, and saw growth in our sales funnel. In addition, we shipped three G4 systems, commenced the broad commercial launch of F3 flow cells and consumable kits and are shipping Max Read kits for single cell sequencing to early access customers,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. “These recent product launches, as well as our growing customer base and strong sales funnel, position us favorably to ramp commercialization of the G4 in the second half of 2023.”
Second Quarter and Recent Highlights
•Generated revenue of $0.5 million in the second quarter of 2023.
•Shipped three G4 systems in the second quarter of 2023, increasing the installed base of commercial systems shipped to 11 as of the end of the second quarter of 2023.
•Commenced the broad commercial launch of the F3 flow cells and consumable kits, allowing users to get up to 450 million reads per flow cell, or 1.8 billion reads per run, for some of the most widely run applications.
•Initiated shipments of Max Read kits for single cell sequencing to early access customers, enabling 800 million reads per flow cell, or 3.2 billion reads per run.
•Expanded commercial infrastructure in Europe to support our international growth strategy.
Second Quarter 2023 Financial Results
Revenue for the second quarter of 2023 was $0.5 million, driven primarily by recognition of sales on two instrument placements.
Operating expenses for the second quarter of 2023 totaled $27.5 million, compared to $24.2 million for the second quarter of 2022. Operating expenses included non-cash stock-based compensation of $2.8 million for the second quarter of 2023 and $3.6 million for the second quarter of 2022. The year over year increase in total operating expenses was driven primarily by scaling headcount, facilities and infrastructure to support commercialization of the G4 and development of our product roadmap.
Net loss for the second quarter of 2023 was $25.6 million, or a loss of $0.35 per common share, compared to $24.0 million, or a loss of $0.34 per common share, in the second quarter of 2022.
Cash, cash equivalents and short-term investments, excluding restricted cash, totaled $206.7 million as of June 30, 2023.
Webcast and Conference Call Details
Singular Genomics’ management team will host a conference call today, August 9, 2023, beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at investor.singulargenomics.com, in the Presentations & Events section.
EX-99.1
About Singular Genomics Systems, Inc.
Singular Genomics is a life science technology company that develops next-generation sequencing and multiomics technologies. The commercially available G4 Sequencing Platform is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in situ readout to look at RNA and proteins in single cells and tissue. With these products, Singular Genomics’ mission is to empower researchers and clinicians to advance science and medicine. Visit www.singulargenomics.com for more information.
Forward-Looking Statements
Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding: (i) our ability to successfully manufacture, commercialize and support the G4 and our F3 flow cells in accordance with our timelines, objectives and specifications; (ii) our ability to close sales in our sales funnel and effectively expand our international commercial presence and customer base; (iii) our ability to release Max Read kits to our broader customer base on our timeline; (iv) the ability of our product offerings to successfully compete with existing and new products offered by our competitors; (v) our ability to achieve customer and scientific acceptance of the G4; and (vi) quotes of management. Any such forward-looking statements are based on our management’s current expectations and are subject to risks and uncertainties that could cause our actual future results to differ materially from our management’s current expectations or those implied by our forward-looking statements. These risks and uncertainties include, but are not limited to, the following: (i) we have incurred significant losses since inception, we expect to incur significant losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability; (ii) we have very little history manufacturing and commercializing our products or technology; (iii) the life sciences technology market is highly competitive, and if we fail to compete effectively, our business and operating results will suffer; (iv) if we are sued for infringing, misappropriating or otherwise violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our products; (v) if our products fail to achieve early customer and scientific acceptance, we may not be able to achieve broader market acceptance for our products, and our revenues and prospects may be harmed; (vi) we expect to be highly dependent upon revenue generated from the sale of the G4 and planned PX, and any delay or failure by us to successfully manufacture and commercialize the G4 and planned PX could have a substantial adverse effect on our business and results of operations; and (vii) recent macroeconomic challenges such as inflation and rising interest rates may materially and adversely impact, our business, operations and product manufacturing and commercialization objectives. These and other risk factors that may affect our future results of operations are identified and described in more detail in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time, including our Quarterly Report on Form 10-Q for the period ended June 30, 2023, filed with the SEC on August 9, 2023. Accordingly, you should not rely on forward-looking statements as predictions of future events or our future performance. Except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
EX-99.1
Investor Contact
Matt Clawson
949-370-8500
ir@singulargenomics.com
Media Contact
Dan Budwick, 1AB
973-271-6085
dan@1abmedia.com
###
EX-99.1
Singular Genomics Systems, Inc.
Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
$ |
505 |
|
|
$ |
- |
|
|
$ |
1,368 |
|
|
$ |
- |
|
Cost of revenue |
|
597 |
|
|
|
- |
|
|
|
1,404 |
|
|
|
- |
|
Gross margin |
|
(92 |
) |
|
|
- |
|
|
|
(36 |
) |
|
|
- |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
12,624 |
|
|
|
12,061 |
|
|
|
24,854 |
|
|
|
22,707 |
|
Selling, general and administrative |
|
14,887 |
|
|
|
12,182 |
|
|
|
28,091 |
|
|
|
23,556 |
|
Total operating expenses |
|
27,511 |
|
|
|
24,243 |
|
|
|
52,945 |
|
|
|
46,263 |
|
Loss from operations |
|
(27,603 |
) |
|
|
(24,243 |
) |
|
|
(52,981 |
) |
|
|
(46,263 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
(270 |
) |
|
|
(167 |
) |
|
|
(529 |
) |
|
|
(309 |
) |
Interest and other income |
|
2,295 |
|
|
|
428 |
|
|
|
4,299 |
|
|
|
584 |
|
Total other income |
|
2,025 |
|
|
|
261 |
|
|
|
3,770 |
|
|
|
275 |
|
Net loss |
$ |
(25,578 |
) |
|
$ |
(23,982 |
) |
|
$ |
(49,211 |
) |
|
$ |
(45,988 |
) |
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted net loss per share |
$ |
(0.35 |
) |
|
$ |
(0.34 |
) |
|
$ |
(0.68 |
) |
|
$ |
(0.65 |
) |
Weighted-average shares used to compute basic and diluted net loss per share |
|
72,510,020 |
|
|
|
70,779,326 |
|
|
|
72,218,280 |
|
|
|
70,893,059 |
|
EX-99.1
Singular Genomics Systems, Inc.
Balance Sheets
(In thousands, except share and par value amounts)
|
|
|
|
|
|
|
|
|
|
|
June 30, |
|
|
December 31, |
|
|
|
2023 |
|
|
2022 |
|
|
|
(Unaudited) |
|
|
|
|
Assets |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
74,817 |
|
|
$ |
74,266 |
|
Short-term investments |
|
|
131,866 |
|
|
|
170,310 |
|
Accounts receivable |
|
|
32 |
|
|
|
913 |
|
Inventory |
|
|
14,354 |
|
|
|
18,221 |
|
Prepaid expenses and other current assets |
|
|
4,624 |
|
|
|
4,722 |
|
Total current assets |
|
|
225,693 |
|
|
|
268,432 |
|
Right-of-use lease assets |
|
|
43,864 |
|
|
|
45,896 |
|
Property and equipment, net |
|
|
11,487 |
|
|
|
10,784 |
|
Restricted cash |
|
|
1,711 |
|
|
|
1,711 |
|
Other noncurrent assets |
|
|
1,223 |
|
|
|
1,152 |
|
Total assets |
|
$ |
283,978 |
|
|
$ |
327,975 |
|
|
|
|
|
|
|
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
1,974 |
|
|
$ |
3,099 |
|
Accrued expenses |
|
|
4,147 |
|
|
|
4,583 |
|
Lease liabilities, current |
|
|
7,607 |
|
|
|
6,323 |
|
Other current liabilities |
|
|
222 |
|
|
|
113 |
|
Total current liabilities |
|
|
13,950 |
|
|
|
14,118 |
|
Lease liabilities, noncurrent |
|
|
40,650 |
|
|
|
42,456 |
|
Long-term debt, net of issuance costs |
|
|
10,136 |
|
|
|
10,065 |
|
Other noncurrent liabilities |
|
|
854 |
|
|
|
1,015 |
|
Total liabilities |
|
|
65,590 |
|
|
|
67,654 |
|
Commitments and contingencies |
|
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
|
Series A common stock equivalent convertible preferred stock, $0.0001 par value; 7,000 shares authorized, 2,500 shares issued and outstanding at June 30, 2023 and December 31, 2022 |
|
|
- |
|
|
|
- |
|
Common stock, $0.0001 par value; 400,000,000 shares authorized, 73,084,481 and 71,854,688 shares outstanding at June 30, 2023 and December 31, 2022, respectively |
|
|
7 |
|
|
|
7 |
|
Additional paid-in capital |
|
|
510,695 |
|
|
|
503,926 |
|
Accumulated other comprehensive loss |
|
|
(328 |
) |
|
|
(837 |
) |
Accumulated deficit |
|
|
(291,986 |
) |
|
|
(242,775 |
) |
Total stockholders’ equity |
|
|
218,388 |
|
|
|
260,321 |
|
Total liabilities and stockholders’ equity |
|
$ |
283,978 |
|
|
$ |
327,975 |
|
v3.23.2
Document and Entity Information
|
Aug. 09, 2023 |
Cover [Abstract] |
|
Entity Registrant Name |
Singular Genomics Systems, Inc.
|
Entity Central Index Key |
0001850906
|
Document Type |
8-K
|
Entity Information, Former Legal or Registered Name |
N/A
|
Document Period End Date |
Aug. 09, 2023
|
Amendment Flag |
false
|
Entity Emerging Growth Company |
true
|
Entity Ex Transition Period |
false
|
Trading Symbol |
OMIC
|
Entity File Number |
001-40443
|
Entity Tax Identification Number |
81-2948451
|
Entity Address, Address Line One |
3010 Science Park Road
|
Entity Address, City or Town |
San Diego
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
92121
|
City Area Code |
858
|
Local Phone Number |
333-7830
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Pre-commencement Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Security Exchange Name |
NASDAQ
|
Entity Incorporation, State or Country Code |
DE
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Singular Genomics Systems (NASDAQ:OMIC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Singular Genomics Systems (NASDAQ:OMIC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024